Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 459-330-2 | CAS number: -
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
Consequences of over-exposure to AE 3000
AGC Inc have received a number of reports (6) from various customers of incidents in which employees have been over exposed to AE 3000. The subjects had been over-exposed in a variety of circumstances in which the common factors were poor ventilation and the absence of respiratory protection. The actual levels of exposure experienced are not known.
The subjects experience various symptoms of CNS depression, including nausea, unsteadiness, dizziness, fainting, convulsions and loss of consciousness. All symptoms were reversible.
Similar symptoms have not been observed in animal studies. On the contrary, in a 28-day inhalation toxicity study in rats, tremors and convulsions were observed following exposure at concentrations of 2000 and 2500 ppm (16.4 and 20.5 mg/I respectively). In a simplified acute toxicity study in rats exposed by inhalation at concentrations up to 3010 ppm (24.6 mg/I), no symptoms of effects on the CNS were reported. However, the study was conducted by nose-only exposure, making observation of animal behaviour during exposure difficult.
3010 ppm is the highest concentration at which rats have been exposed to AE 3000 in any inhalation toxicity study. It remains possible that the subjects that experienced adverse effect were exposed to higher concentrations of AE 3000, which might explain the apparent discrepancy between species.
Justification for classification or non-classification
As a consequence of the findings in humans following over exposure to AE 3000, it is concluded that the substance should be classified STOT-SE Category 3 and assigned the phrase H336 “May cause dizziness and drowsiness".
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
